Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac Arrhythmia AND Arrhythmia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    158 result(s) found for: Cardiac Arrhythmia AND Arrhythmia. Displaying page 5 of 8.
    « Previous 1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2006-006404-11 Sponsor Protocol Number: PERFECT001(M-2006-144) Start Date*: 2008-03-19
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: INTRAMYOCARDIAL TRANSPLANTATION OF BONE MARROW STEM CELLS FOR IMPROVEMENT OF POST-INFARCT MYOCARDIAL REGENERATION IN ADDITION TO CABG SURGERY: a controlled prospective, randomized, double blinded m...
    Medical condition: Coronary artery disease after myocardial infarction with an indication for CABG surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10028596 Myocardial infarction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000868-42 Sponsor Protocol Number: B3461045 Start Date*: 2016-09-26
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR...
    Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10002020 Amyloid cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002060-17 Sponsor Protocol Number: 2015/077/HP Start Date*: 2015-08-21
    Sponsor Name:CHU - Hôpitaux de Rouen
    Full Title: Effect of pharmacological heart rate reduction on visco-elastic properties of the arterial wall - Impact of aging
    Medical condition: Healthy subjects between 25 and 65 years old
    Disease: Version SOC Term Classification Code Term Level
    18.0 10022891 - Investigations 10007574 Cardiac imaging procedures HLT
    18.0 10022891 - Investigations 10052677 Vascular imaging PT
    18.0 10007541 - Cardiac disorders 10006093 Bradycardia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-005351-27 Sponsor Protocol Number: 2015CD007B Start Date*: 2016-02-17
    Sponsor Name:Royal Brompton & Harefield NHS Foundation Trust
    Full Title: A randomised controlled pilot trial of the feasibility and safety of therapy withdrawal in asymptomatic patients with a prior diagnosis of dilated cardiomyopathy & recovered cardiac function.
    Medical condition: Dilated Cardiomyopathy with recovered cardiac function
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-000187-15 Sponsor Protocol Number: MK-8616-145 Start Date*: 2017-09-18
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecu...
    Medical condition: Reversal of neuromuscular blockade
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10018061 General anesthesia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-000619-51 Sponsor Protocol Number: FX06AQ-II-01 Start Date*: 2006-07-10
    Sponsor Name:Fibrex Medical Research & Development GmbH
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Measure the Effect of FX06 (a fibrin derived peptide Bβ15-42) on Ischemia-Reperfusion Injury in Patients Undergoing Primary Perc...
    Medical condition: Patients with acute myocardial infarction (AMI) indicated for Percutaneous Coronary Intervention (PCI).
    Disease: Version SOC Term Classification Code Term Level
    8.0 10000891 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) DK (Completed) AT (Completed) NL (Completed) CZ (Completed) BE (Completed) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000588-26 Sponsor Protocol Number: ICCE12.001 Start Date*: 2012-10-16
    Sponsor Name:Leiden University Medical Center
    Full Title: Pharmacokinetics of Levosimendan in children with acute heart failure
    Medical condition: Acute heart failure in children
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013112-12 Sponsor Protocol Number: REGENERATE/DCM/2.0 Start Date*: 2010-04-22
    Sponsor Name:Barts & the London NHS Trust
    Full Title: Randomised Controlled Trial To Compare The effects of G-CSF(Granocyte™) And Autologous Bone Marrow Progenitor Cells On Quality Of Life And Left Ventricular Function In Patients with Idiopathic Dila...
    Medical condition: Idiopathic Dilated Cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    10056419 Dilated Cardiomyopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001382-10 Sponsor Protocol Number: CS/2015/4775 Start Date*: 2019-01-21
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: Treatment of Barth Syndrome by CARDIOlipin MANipulation (CARDIOMAN): A randomised placebo controlled pilot trial conducted by the nationally commissioned Barth Syndrome Service
    Medical condition: Barth Syndrome is a rare, life threatening, genetic disease which affects young males. It is caused by abnormal fats (lipids) in the powerhouses of cells (mitochondria) and those who suffer with it...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-005022-18 Sponsor Protocol Number: PACeS Start Date*: 2022-07-26
    Sponsor Name:Icahn School of Medicine at Mount Sinai
    Full Title: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG
    Medical condition: New-Onset Post-Operative Atrial Fibrillation after CABG
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005887-14 Sponsor Protocol Number: B1321003 Start Date*: 2010-01-12
    Sponsor Name:Pfizer Ltd.
    Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, EFFICACY AND SAFETY STUDY OF MONOTHERAPY SITAXSENTAN SODIUM VERSUS COMBINATION THERAPY WITH SITAXSENTAN SODIUM AND SILDENAFIL CITRATE IN SUBJECTS ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005072-40 Sponsor Protocol Number: 1235-SR-202-AF Start Date*: 2007-03-12
    Sponsor Name:Cardiome Pharma Corp.
    Full Title: Vernakalant (oral) Prevention of Atrial Fbrillation Recurrence Post-Conversion Study
    Medical condition: Atrial fibrillation is the most common arrhythmia encountered in clinical practice. Atrial fibrillation is usually associated with age and general physical condition, rather than with a specific ca...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066664 Recurrent symptomatic atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) DE (Completed) DK (Completed) SK (Completed) HU (Completed) EE (Completed) BG (Completed) LT (Completed) ES (Completed) CZ (Completed) PT (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005326-38 Sponsor Protocol Number: DIGIT-HF Start Date*: 2015-03-19
    Sponsor Name:Hannover Medical School
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients ...
    Medical condition: Advanced systolic chronic heart failure NYHA class III-IV and EF ≤ 40% or NYHA class II and EF ≤ 30%
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005849-16 Sponsor Protocol Number: KIN001-203 Start Date*: 2021-03-09
    Sponsor Name:Kinarus AG
    Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient...
    Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084272 SARS-CoV-2 infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004445-17 Sponsor Protocol Number: AP30663-2001 Start Date*: 2021-06-29
    Sponsor Name:Acesion Pharma ApS
    Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-022947-39 Sponsor Protocol Number: CV203-010 Start Date*: 2011-03-18
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Randomized, Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Safety, Tolerability and Effect on Atrial Fibrillation Burden of BMS-914392 in Patients with Paroxysmal Atrial Fi...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10003661 Atrial fibrillation paroxysmal LLT
    14.1 10007541 - Cardiac disorders 10034039 Paroxysmal atrial fibrillation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005352-41 Sponsor Protocol Number: TACT-2C-TRIAL Start Date*: 2014-09-05
    Sponsor Name:AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI CREMONA
    Full Title: A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 pos...
    Medical condition: Metastatic Breast Cancer in HER2- positive CTC with primary HER2-negative.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-009928-37 Sponsor Protocol Number: CONKO-008 Start Date*: 2009-10-21
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: Phase 1/2 Studie: CONKO-008 Oxaliplatin/Folinsäure/5-Fluorouracil (24h) in Kombination mit Lapatinib in der Zweitlinientherapie des Pankreaskarzinoms nach Progress unter Gemcitabin-Monotherapie
    Medical condition: Pancreatic cancer patients who failed first line therapy with gemcitabine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004822-85 Sponsor Protocol Number: ABCSG-34 Start Date*: 2012-01-05
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: A prospective, open, randomized, phase-II study of a therapeutic cancer vaccine (L-BLP25, Stimuvax®) in the pre-operative treatment of women with primary breast cancer
    Medical condition: primary breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001614-38 Sponsor Protocol Number: S63935 Start Date*: 2020-04-22
    Sponsor Name:UZLeuven
    Full Title: Covid-19: A randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2.
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10038700 Respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 10:03:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA